iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
JAZZ - Jazz Pharmaceuticals plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$258.50
DETAILS
HIGH:
$307.00
LOW:
$229.00
MEDIAN:
$252.50
CONSENSUS:
$258.50
UPSIDE:
4.69%
Stock News
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?
Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesday.
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration DUBLIN and VANCOUVER, BC, June 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
Jazz Pharmaceuticals lung cancer drug fails main trial goal
Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca failed to meet the main goal of improving overall survival in a late-stage study, potentially risking its current regulatory status.
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan.
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophageal adenocarcinoma (GEA), according to BofA Securities.
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia.
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line setting Additional subgroup analyses to be presented at the 2026 ASCO Annual Meeting show improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients For U.S. media and investors only DUBLIN, May 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safety profile of Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with and without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. The manuscript builds on the late-breaking oral presentation of the HERIZON-GEA-01 trial results at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI), where zanidatamab-containing combinations demonstrated unprecedented progression-free survival (PFS) and overall survival (OS) outcomes in a global Phase 3 trial.
Price Targets
Jazz Pharmaceuticals price target raised to $270 from $250 at Deutsche Bank
$270.00
(was $249.63)
Deutsche Bank
Jazz Pharmaceuticals price target lowered to $254 from $256 at Truist
$254.00
(was $245.54)
Gregory Renza
·
Truist Financial
Truist Securities Assumes Jazz Pharmaceuticals (JAZZ) at Buy
$256.00
(was $232.04)
Gregory Renza
·
Truist Financial
Jazz Pharmaceuticals price target raised to $253 from $234 at Barclays
$253.00
(was $237.41)
Barclays
Jazz Pharmaceuticals price target raised to $301 from $232 at Piper Sandler
$301.00
(was $239.40)
Piper Sandler
Jazz Pharmaceuticals initiated with a Market Perform at Bernstein
$229.00
(was $239.40)
Bernstein
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
$307.00
(was $229.55)
Ashwani Verma
·
UBS
Jazz Pharmaceuticals price target raised to $245 from $226 at Morgan Stanley
$245.00
(was $224.52)
Sean Laaman
·
Morgan Stanley
Jazz Pharmaceuticals price target raised to $239 from $227 at Raymond James
$239.00
(was $227.88)
Tiago Fauth
·
Raymond James
Jazz Pharmaceuticals price target raised to $252 from $209 at Baird
$252.00
(was $212.26)
Robert W. Baird
Jazz Pharmaceuticals price target raised to $234 from $225 at Barclays
$234.00
(was $212.26)
Etzer Darout
·
Barclays
Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays
$225.00
(was $203.42)
Etzer Darout
·
Barclays
Jazz Pharmaceuticals resumed with an Outperform at Raymond James
$227.00
(was $193.18)
Raymond James
Barclays Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)
$224.00
(was $185.40)
Etzer Darout
·
Barclays
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham
$235.00
(was $161.13)
Ami Fadia
·
Needham
Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley
$225.00
(was $169.37)
Sean Laaman
·
Morgan Stanley
Jazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler
$219.00
(was $162.26)
David Amsellem
·
Piper Sandler
Jazz Pharmaceuticals downgraded to Neutral from Buy at UBS
$188.00
(was $176.93)
Ashwani Verma
·
UBS
Jazz Pharmaceuticals price target raised to $194 from $155 at RBC Capital
$194.00
(was $170.14)
RBC Capital
Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
$205.00
(was $170.16)
Sean Laaman
·
Morgan Stanley